# FAT4

Source: https://onco.cc/targets/fat4/  
OnCo record `fat4` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FAT4 (Protocadherin Fat 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Colorectal cancer, Hepatocellular carcinoma and 5 more.

## Summary

Cadherins are calcium-dependent cell adhesion proteins. FAT4 plays a role in the maintenance of planar cell polarity as well as in inhibition of YAP1-mediated neuroprogenitor cell proliferation and differentiation.

Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes literature 0.97, animal model 0.39, genetic association 0.36, somatic mutation 0.90). IntOGen calls it a driver in 37 cohorts (24 activating, 12 loss-of-function), covering Adrenocortical Carcinoma, Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Anal Squamous Cell Carcinoma, Basal Cell Carcinoma, Invasive Breast Carcinoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: FAT atypical cadherin 4; Protocadherin Fat 4; CDHF14; FAT-J; CDHR11
- Tags: cancer-genes-wave
- Symbol: FAT4
- Class: oncogene
- Biology: Cadherins are calcium-dependent cell adhesion proteins. FAT4 plays a role in the maintenance of planar cell polarity as well as in inhibition of YAP1-mediated neuroprogenitor cell proliferation and differentiation. Location: Membrane (UniProt). Locus 4q28.1 (HGNC).
- Where found: Prostate cancer: IntOGen driver in 4 cohorts (PRAD); Colorectal cancer: Open Targets association 0.62 with colorectal cancer (MONDO_0005575); IntOGen driver in 1 cohort (COADREAD); Hepatocellular carcinoma: IntOGen driver in 3 cohorts (HCC); Breast cancer: Open Targets association 0.60 with breast cancer (MONDO_0007254); IntOGen driver in 2 cohorts (BRCA); Gastric & gastro-oesophageal junction cancer: Open Targets association 0.56 with gastric cancer (MONDO_0001056); IntOGen driver in 2 cohorts (STAD, STOMACH); Oesophageal cancer: Open Targets association 0.50 with oesophageal cancer (MONDO_0007576); IntOGen driver in 2 cohorts (ESCA)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 24 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 12 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:23109: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23109
- UniProt Q6V0I7: https://www.uniprot.org/uniprotkb/Q6V0I7/entry
- NCBI Gene 79633: https://www.ncbi.nlm.nih.gov/gene/79633
- Ensembl ENSG00000196159: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196159

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/fat4.json